Indication :Â The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy The treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. Compositions : Each vial contain Bortezomib 3.5 mg Storage Condition :Â When […]
Indication : Malignant Pleural Mesothelioma PEMECINE® in combination with Cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer PEMECINE® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly
Ovarian carcinoma First-line therapy in combination with a platinum compound for the treatment of advanced metastatic carcinoma of the ovary. Second-line therapy for the treatment of advanced metastatic carcinoma of the ovary. Breast carcinoma Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy. Therapy after relapse within 6 months of adjuvant
Indication : Breast cancer Non-small cell lung cancer Prostate cancer Gastric adenocarcinoma Head and neck cancer Ovarian cancer Compositions : Each mL contain Docetaxel trihydrate 21.34 mg ~ Docetaxel 20 mg Storage Condition : Do not store above 30°C. Store in the original package in order to protect from light. Keep out the
Indication : Oxaliplatin in combination with 5-Fluorouracil (5-FU) and folinic acid (FA) is indicated for: adjuvant treatment of stage III (Duke’s C) colon cancer after complete resection of primary tumor treatment of metastatic colorectal cancer Compositions : Each mL contain Oxaliplatin 5 mg Storage Condition : Store below 30°C, in a hermetic container.Â
Indication : KEMODOXIN® is indicated for regression in disseminated neoplastic conditions such as acute leukemia, Wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, lung cancer, Hodgkin’s disease and non-Hodgkin’s lymphoma, bronchogenic carcinoma, and gastric carcinoma. Compositions : Each mL contain Doxorubicin hydrochloride 2 mg
Indication :Â Epirubicin HCl administered as single agent has shown to produce regression in a broad spectrum of tumors including mammary carcinoma, malignant lymphomas, soft tissue sarcomas and gastric cancer. Preliminary findings indicate that the drug has produce some anti tumor activity in malignant melanoma and in advanced colorectal carcinoma. Given in combination with other
Indication : advanced ovarian carcinoma small cell and non small cell carcinoma of the lung squamous cell carcinoma of the head and neck advanced transitional cell carcinoma of the bladder significant responses have been observed when KEMOBOTIN® employed in the treatment of carcinoma of the cervix. KEMOBOTIN® is frequently used in combination with other chemotherapeutic
Indication : Non-small cell lung cancer Pancreatic cancer Bladder cancer Breast cancer Ovarian cancer Other therapeutic activity: Gemcitabine alone or in combination has shown activity in advanced breast and ovarian cancer. Compositions : Each mL contain Gemcitabine hydrochloride 43.27 mg ~ Gemcitabine 38.005 mg Storage Condition : Store in refrigerator (2 – 8°C).
Indication : Methotrexate is indicated in the treatment gestational chroriocarcinoma, chorio adenoma destruens and hydatidiform mole. In acute lymphatic leukemia, Methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agent, Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone
Indication :Â The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy The treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. Compositions : Each vial contain Bortezomib 3.5 mg Storage Condition :Â When
Indication : Malignant Pleural Mesothelioma Pemetrexed in combination with Cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly
Contact CKD OTTO Pharma now for more information about our products and services.
